LitAlert ~~ GeneLit.com

    • Differences in age at diagnosis of ovarian cancer for each BRCA mutation type in Japan: optimal timing to carry out risk-reducing salpingo-oophorectomy.
    • Sekine M, Enomoto T, Arai M, Den H, Nomura H, Ikeuchi T, Nakamura S, and the Registration Committee of the Japanese Organization of Hereditary Breast and Ovarian Cancer.
    • J Gynecol Oncol. 2022 Jul;33(4):e46. doi: 10.3802/jgo.2022.33.e46. Epub 2022 Mar 31.
    • 3

    • Bone health after RRBSO among BRCA1/2 mutation carriers: a population-based study.
    • Abreu do Valle H, Kaur P, Kwon JS, Cheifet R, Dawson L, Hanley GE.
    • J Gynecol Oncol. 2022 Jul;33(4):e51. doi: 10.3802/jgo.2022.33.e51. Epub 2022 Mar 30.
    • Hereditary breast cancer and fertility preservation outcomes.
    • Arab S, Tulandi T, Buckett W.
    • Assist Reprod Genet. 2022 Apr 11. doi: 10.1007/s10815-022-02486-0. Epub ahead of print.
    • Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial.
    • Li N, Zhang Y, Wang J, Zhu J, Wang L, Wu X, Yao D, Wu Q, Liu J, Tang J, Yin R, Lou G, An R, Zhang G, Xia X, Li Q, Zhu Y, Zheng H, Yang X, Hu Y, Zhang X, Hao M, Huang Y, Lin Z, Wang D, Guo X, Yao S, Wan X, Zhou H, Yao L, Yang X, Cui H, Meng Y, Zhang S, Qu J, Zhang B, Zou J, Wu L.
    • J Clin Oncol. 2022 Apr 11:JCO2101511. doi: 10.1200/JCO.21.01511. Epub ahead of print.